Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
Health Technology » Pharmaceuticals Major
|JNJ||Johnson & Johnson||0.19%||163.53||0.7%||$1333.35m|
|LLY||Eli Lilly & Co.||0.74%||324.00||1.1%||$1075.83m|
|BMY||Bristol-Myers Squibb Co.||-0.01%||70.53||1.0%||$772.67m|
|MRK||Merck & Co., Inc.||0.46%||87.96||0.7%||$713.70m|
|ALNY||Alnylam Pharmaceuticals, Inc.||0.00%||196.79||8.2%||$217.39m|
|ATXI||Avenue Therapeutics, Inc.||42.92%||16.45||0.0%||$199.10m|
|GBT||Global Blood Therapeutics, Inc.||0.00%||68.48||5.4%||$191.16m|
|IDXX||IDEXX Laboratories, Inc.||1.10%||340.39||3.9%||$186.31m|
|HZNP||Horizon Therapeutics Plc||0.00%||64.26||5.4%||$173.65m|
|SRPT||Sarepta Therapeutics, Inc.||0.00%||109.94||12.4%||$136.73m|
Dyax Corp. (Dyax) is a biopharmaceutical company focused on the discovery, development and commercialization of biotherapeutics for unmet medical needs, with an emphasis on inflammatory and oncology indications. The Company's lead product, DX-88, has been approved under the brand name KALBITOR (ecallantide) by the United States Food and Drug Administration (FDA) for treatment of acute attacks of hereditary angioedema (HAE) in patients 16 years of age and older. The Company commercializes KALBITOR on its own in the United States. In addition to its approved commercial use for HAE in the United States, the Company is also developing DX-88 through collaborations in other indications. These include use of DX-88 for the reduction of blood loss during surgery in collaboration with Cubist Pharmaceuticals (Cubist), and for treatment of retinal diseases in collaboration with Fovea Pharmaceuticals (Fovea), which was acquired by sanofi-aventis during the year ended December 31, 2009.